TScan Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $17.5M
- Price
- $0.2754
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.74%
- Volume
- 609.5K
About
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Quick stats
Shares outstanding63.5M
Computed float60.6M
Float / shares95.4%
Cash runway (months)7.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001783328
Websitehttps://www.tscan.com
AI Summary
AI-generated1/12
majormixedrestructuring
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
TScan Therapeutics is reorganizing around its in vivo-engineered TCR-T program for solid tumors, advancing two candidates targeting PRAME and MAGE-A4 into IND-enabling studies with a first IND filing planned for Q3 2027 and Phase 1 initiation in Q4 2027.
Enrollment in the Phase 3 ALLOHA-2 study of TSC-101 in heme malignancies is paused due to insufficient capital, though 7 enrolled patients continue to be followed; updated Phase 1 ALLOHA data show all 13 tracked Cohort C patients with complete donor chimerism, including two who had relapsed.
The restructuring includes a workforce reduction of approximately 75%, elimination of the internal manufacturing organization, and cumulative cost savings of $55.0 million through the end of 2027, extending cash runway into Q4 2027.
TScan is actively seeking strategic partnerships for its heme and autoimmune programs, with data updates planned on Cohort C in Q4 2026.
Red flags
- Phase 3 ALLOHA-2 enrollment paused because the company cannot access capital to complete the pivotal trial
- Approximately 75% workforce reduction at a clinical-stage biotech
- Cash runway only into Q4 2027; future value hinges on securing a partnership or new capital
- Lead heme program deprioritized despite positive data; pivot targets are still preclinical with Phase 1 not until Q4 2027
- One non-relapse mortality reported in Cohort C (disclosed as unrelated to TSC-101)